Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-021 (Avegra) vs Avastin in Advanced Non-Squamous NSCLC
NCT01763645Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Oct 2012
- Primary completion
- Nov 2014
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab biosimilar BCD-021 in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by BIOCAD. Primary endpoints: Overall Response Rate at Day 127 and Area Under the Curve After the First Test Drug Administration at Day 22. Started Oct 2012; status: completed.
02
Drugs
bevacizumab biosimilar BCD-021
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01763645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01763645.